CD8A and non-Hodgkin lymphoma: Furthermore, when compared to pretherapy NHL subjects, EMAP II+CD4+%, EMAP II+CD8+%, and EMAP II+CD20+% were lower in NHL patients with recurrence (P = 0.001) (Figure 1 and Table 2).